Frontlight ResearchEarly access
CompletedNo phase
Remote Treatment of Alcohol Withdrawal
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 24 Sept 2021
- Ended
- 21 Nov 2023
- Type of study
- Interventional
- Treatments tested
- Diazepam
- Record updated
- 14 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adults 18 years and older
- Are actively using alcohol
- Previously met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) B criteria for alcohol withdrawal
- Aim to achieve at least 30 days of abstinence as a treatment goal following initiation of remote alcohol withdrawal management
- Are able to provide informed consent in English
- Reside or are able to stay at an address within 2-hours travelling distance from the Centre for Addiction and Mental Health for the entire duration of the remote withdrawal procedure
- Are enrolled in the Ontario Health Insurance Plan (OHIP)
Who cannot take part
- History of complicated withdrawal including withdrawal seizures, hallucinosis, or delirium
- Positive UDS for sedatives or opioids, currently prescribed sedatives or opioids, or diagnosis of sedative-hypnotic or opioid use disorder within the past year (based on assessment). Individuals prescribed low doses of benzodiazepines (e.g. lorazepam 1mg PO daily) or with a positive urine benzodiazepine screen that is not thought to be due to benzodiazepine misuse may be permitted to proceed with the study at the discretion of the study physician
- Severe medical or psychiatric comorbidity that would prevent safe participation in the study
- Contraindications to the safe use of diazepam including: known hypersensitivity to diazepam severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome, acute narrow-angle glaucoma, and myasthenia gravis. Individuals with sleep apnea may be permitted to proceed with the study at the discretion of the study physician
- Active withdrawal symptoms (CIWA-Ar > 12) at the time of the eligibility assessment
- Active suicidal ideation at the time of eligibility assessment
- Positive urine pregnancy test, actively breastfeeding, or planning to become pregnant or breastfeed during the study period
- Lack of stable housing
- Enrollment in another study that conflicts with the procedures or scientific integrity of this study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the feasibility of delivering symptom-triggered alcohol withdrawal management by telemedicine and determine whether this intervention is satisfactory to patients.
The group in the trial
- Symptom-triggered diazepam treatmentTreatment being tested
Participants will be treated for a period of 3 days using a symptom-triggered withdrawal management protocol delivered over telemedicine. Participants who score 10 or above on the modified CIWA-Ar will be advised to take a specific dose of diazepam (either 10 or 20mg, at the clinician's discretion). Participants will be reassessed regularly over the 3-day period.
Treatment: Diazepam
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Remote Treatment of Alcohol Withdrawal: A Pilot Study
- Record updated
- 14 May 2026